Provention Bio, Inc. (PRVB)
| Market Cap | 954.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -76.55M |
| Shares Out | 56.34M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $14.53 |
| Previous Close | $15.22 |
| Change ($) | -0.69 |
| Change (%) | -4.53% |
| Day's Open | 15.22 |
| Day's Range | 13.91 - 15.30 |
| Day's Volume | 1,698,401 |
| 52-Week Range | 5.42 - 19.45 |
BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/ -- Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated c...
RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...
RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2...
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...
RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...
RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...
RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...
RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that...
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financ...
Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rollin...
RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the c...
RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that...
RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a n...
RED BANK, N.J., Sept. 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announce...
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc.
OLDWICK, N.J., Aug. 31, 2020 /PRNewswire/ -- Provention Bio, Inc.
Each of these companies has the potential to generate life-changing returns.
OLDWICK, N.J., Aug. 11, 2020 /PRNewswire/ -- Provention Bio, Inc.
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2020 Results - Earnings Call Transcript
OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc.
Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon
Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon
Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.
OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced toda...
OLDWICK, N.J., June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced toda...
OLDWICK, N.J., June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...
OLDWICK, N.J., June 16, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...
Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The company released positive data from a clinical trial for one of its pipeline candidates.
The company released positive data from a clinical trial for one of its pipeline candidates.
OLDWICK, N.J., June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...
OLDWICK, N.J., May 28, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced ...
OLDWICK, N.J., May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, t...
OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune...
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2020 Results - Earnings Call Transcript
When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment.
Provention Bio: The First Type 1 Diabetes Breakthrough In A 100 Years
Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Provention Bio: Discounted Price, Insider Buying, And Catalysts Frame The Opportunity
Efforts to stem the coronavirus outbreak are liable to disrupt the protocols of a lot of drug trials.
The decision was made to protect the safety of those involved.
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2019 Results - Earnings Call Transcript
Provention Bio: A Buy On Type 1 Diabetes Opportunity And Clear Path To Approval
Provention Bio: A Promising Small-Cap Immuno-Endocrinology Player For 2020
It's a $45 billion market -- here are some winners that could keep winning.
About PRVB
Provention Bio, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus;... [Read more...]
| Industry Biotechnology | |
| CEO Ashleigh Palmer | Employees 19 |
| Stock Exchange NASDAQ | Ticker Symbol PRVB |
Analyst Forecasts
According to 6 analysts, the average rating for Provention Bio stock is "Strong Buy." The 12-month stock price forecast is 29.00, which is an increase of 99.59% from the latest price.